BioCircuit Technologies Closes $9 Million Series Seed Round

BioCircuit Technologies is $9 million richer these days, having closed a round of financing that included support from Mike Masters of Masters Capital, the GRA Venture Fund, Alsora Capital, and existing shareholders.  

BioCircuit has received more than $7 million in funding from numerous NIH grants and including this round, has attracted over $13.5 million in private financing.

“We are very grateful to our investors for the support they have shown and continue to show for BioCircuit,” BioCircuit CEO Michelle Jarrard said. “The company has achieved a number of important milestones during the last year, including FDA 510(k) clearance for our first device, and we are now in a position to scale with confidence.”
 
The money from this round will be used to commercialize BioCircuit’s nerve repair device, Nerve Tape. The product’s patented design is the first U.S. Food and Drug Administration-cleared, suture-less solution to surgically repair damaged nerves. In addition, funds will support the further development of BioCircuit’s therapeutic device designed to improve the gait of patients afflicted with spinal cord injuries, stroke, and a variety of other neurological conditions. First human use is scheduled to occur in 2023. 
 
“BioCircuit’s products address compelling patient needs and represent sizable market opportunities in the fields of nerve repair and neurorehabilitation. I have personally invested in BioCircuit over the last several years based on my assessment of its technologies, intellectual property position, and the capabilities of the team,” BioCircuit board member Mike Masters said. 
 
“BioCircuit’s strategy is to develop products that translate the insights of preeminent researchers into broad clinical application, to improve patient outcomes for those who would not otherwise have access to these therapeutic options,” BioCircuit Board Chair and former Axion Biosystems CEO Tom O’Brien said. “The funds raised in this round will enable the company to make meaningful progress in bringing its first product to market, and we are excited about Nerve Tape’s potential in the field of nerve repair.” 
 
Based in Atlanta, BioCircuit Technologies develops and commercializes medical devices for tissue repair and neuromodulation. Designed for ease-of-use and reliability, these devices enhance therapeutic targeting, diagnostic precision, and surgical consistency for improved patient outcomes.